Biomark obtains Asia patents for lung cancer test

Executive Summary

• Biomark Diagnostics received formal patents for its metabolic liquid‑biopsy platform in China (ZL 201980092723.X) and Japan (2023‑111262).
• The patented technology demonstrated >90% sensitivity for early‑stage lung cancer in a peer‑reviewed study, positioning the company as a market leader.
• Patents open pathways for commercial expansion, licensing deals, and strategic partnerships across Asia’s two largest healthcare markets.

Key Details

• Patents Granted:
• China – Patent No. ZL 201980092723.X covering metabolite‑based lung cancer detection.
• Japan – Patent No. 2023‑111262 covering the same technology.
• Technology Performance: Over 90% sensitivity for early‑stage lung cancer in a study published in International Journal of Molecular Sciences.
• Market Opportunity:
• China liquid‑biopsy market projected to exceed US$670 million by 2030.
• Japan liquid‑biopsy market projected to exceed US$912 million by 2030.
• Strategic Impact: Strengthens Biomark’s global IP estate; enables potential licensing, joint‑development, and commercial agreements in Asia.
• Leadership Quote: Rashid Ahmed Bux (President & CEO) described the patents as a “transformational milestone” that aligns with the next wave of liquid biopsy adoption and will drive expansion and partnerships.

Notable Quotes

"Securing these patents in two of Asia's largest health care markets is a transformational milestone for Biomark," said Rashid Ahmed Bux, president and chief executive officer of Biomark. "Our technology is directly aligned with the next wave of liquid biopsy adoption across the region… opening up new opportunities for expansion, technology licensing and strategic partnerships."